11/3/2026

speaker
Conference Operator
Operator

Good afternoon, and welcome to the CuraLeaf Holdings, Inc., third quarter, 2026 conference call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on a touch-tone phone. To withdraw your question, please press star, then two. Please note this event is being recorded. I would now like to turn the conference over to Camilo Lyon, Chief Investment Officer. Please go ahead.

speaker
Camilo Lyon
Chief Investment Officer

Good afternoon, everyone, and welcome to Curaleaf Holdings' third quarter 2026 conference call. Today, I'm joined by Chairman and Chief Executive Officer Boris Jordan, President Rahul Pinto, and Chief Financial Officer Ed Kremer. Before we begin, I'd like to remind everyone that the comments on today's call will include forward-looking statements within the meaning of Canadian and United States securities laws, which by their nature involve estimates, projections, plans, goals, forecasts and assumptions, including the successful integration of acquisitions and are subject to risks and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements on certain material factors or assumptions that were applied in drawing the conclusion or making a forecast in such statements. These forward-looking statements speak only as of the date of this conference call and should not be relied upon as predictions of future events. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law. Additional information about the material factors and assumptions forming the basis of the forward-looking statements and risk factors can be found in the company's filings and press releases on CDAR and EDGAR. During today's conference call, in order to provide greater transparency regarding Curalease operating performance, we will refer to certain non-GAAP financial measures and non-GAAP financial ratios that involve adjustments to GAAP results. Such non-GAAP measures and ratios do not have a standardized meaning under US GAAP. Any non-GAAP financial measures presented should not be considered to be an alternative to financial measures required by US GAAP, should not be considered measures of cure-lease liquidity, and are unlikely to be comparable to non-GAAP financial measures provided by other companies. Any non-GAAP financial measures referenced on this call are reconciled to the most directly comparable US GAAP financial measure under the heading Reconciliation of Non-GAAP Financial Measures in our earnings press release issued today and are available on our investor relations website at ir.cureleaf.com. With that, I'll turn the call over to Chairman and CEO, Boris Jordan.

speaker
Boris Jordan
Chairman and Chief Executive Officer

Boris? Thank you, Camilo. Good afternoon, everyone, and thank you for joining us to discuss our third quarter results. We're building a global leader in cannabis, and our third quarter results are further proof that our strategy is delivering. Disciplined execution across the business is driving profitable growth, strengthening our competitive position, and advancing our built-for-growth plan. We are raising cultivation yields, elevating product quality, scaling our brand portfolio, and leveraging our global distribution platform, all while maintaining rigorous cost discipline and keeping the customer at the center of everything we do. These initiatives are producing tangible results, enhancing the earnings power of our business, and positioning Curaleaf to capture the significant opportunities ahead. We have made substantial progress and believe we are still in the early stages of realizing the full potential of our global platform. Turning to the quarter, against a backdrop of increasing pressure on the consumer, cannabis demand remained resilient and our business delivered strong broad-based growth. Record third quarter revenue increased 11% year-over-year to $353 million, with our domestic and international segments growing 8% and 28% respectively. adjusted gross margin was 49% and adjusted EBITDA reached 78 million, representing a 22% margin, inclusive of 120 basis point drag from international. We ended the quarter with 105 million in cash, providing a solid foundation to support our strategic priorities. Our domestic business delivered its third consecutive quarter of year-over-year growth, demonstrating that our initiatives are gaining traction and customers are responding to improvements across the business. Our cultivation performance continues to be a significant driver of that progress. We are achieving higher yields across our network, with some markets surpassing 120 grams per foot, while materially improving potency, terpene profiles, and an overall flower quality. We are increasingly translating those gains across our product portfolio, strengthening our brands, and creating greater flexibility around pricing, promotions, and mix. The result is a stronger consumer proposition and a more productive economic model for our business. While price compression remains prevalent across most markets, we are seeing some encouraging signs of stabilization. Price compression in our retail dispensaries is moderating in several markets, largely due to actions we have taken with Massachusetts and Illinois now showing two consecutive quarters of increases. Improving supply-demand dynamics coupled with the anticipated hemp shutdown in December could provide additional support to the pricing environment. At the same time, we remain mindful of pressure on the consumer from higher energy costs and rising interest rates. That domestic operating momentum also extends to Curaleaf International, which delivered another quarter of exceptional growth with revenue reaching 59 million, up 14% sequentially. Our two largest markets, the UK and Germany, led the performance supported by continued growth in Poland. The breadth of this performance reinforces our confidence in the scale and long-term potential of our international platform. In the UK, continued growth in active patients and Curaleaf Clinic drove solid results, while our wholesale business also performed well, particularly across flour and pastilles. Together, these results strengthened our number one market position and demonstrated the advantages of the vertically integrated platform we have built. In Germany, demand remains healthy. but irrational pricing by certain Canadian competitors is accelerating price compression and could temper our fourth quarter growth. Alongside other operators, we are working with regulators to address violations of greenwashing laws by bad actors. The UK offers a relevant precedent. Its regulator acted quickly to rein in similar practices, and that market is showing healthy growth. We expect enforcement action in Germany, although the timing remains uncertain. Despite these transitory pressures, our Hwala and Curaleaf branded strains are outperforming and contributing to the segment's growth, demonstrating our team's continued execution. Robust orders from our Q medical inhalation device are also helping offset pricing pressure in flour. Our brand's product quality and distribution capabilities continue to differentiate Curaleaf in one of Europe's most important cannabis markets. Beyond our established markets, we continue to expand Our reach and position purely for the next wave of international growth. In Spain, following our first two cannabis preparation registrations in July, we received our third registration in October, giving us what's needed to bring a broad portfolio of products to patients. While the government has taken longer than anticipated to establishing the purchasing infrastructure for hospitals, indicative demand for our products is strong and we expect to begin fulfilling sales this month in France. Several years of investment and preparation have culminated in a distribution partnership with a prominent pharmaceutical company. This positions Curaleaf well for the expected launch of the market in 2027. Importantly, the program is expected to include insurance reimbursement, which we believe can support sustained patient adoption as the market develops. In Turkey, the rulemaking process is underway with the regulatory framework expected to take shape in early 2027. that should position us to begin product manufacturing by the second half of the year. In Australia, QMID was the first cannabis-specific inhalation device to receive regulatory registration approval by the Therapeutic Goods Administration, marking another first for the team. The following day, New Zealand also made the device available to its patients. We continue to see growing demand for QMID across our international markets and believe there's meaningful opportunity to expand its presence further. We are also expanding institutional access to Curaleaf shares and strengthening our position in the capital markets. In September, Curaleaf was added to the FTSE Russell All Cap Canada Index, our second major index inclusion following our addition to the S&P TSX last year. These milestones are increasing our visibility among institutional investors and broadening our potential shareholder base. Leading institutional investors, including BlackRock and Vanguard, have established positions in Curaleaf complementing our significant founder-led investor base and increasing the stability of our equity capital structure. JPMorgan has also become a custodian of our shares complementing coverage across the four largest global custodial banks and removing important barriers to institutional ownership. Additional index inclusions could broaden participation further. Finally, we remain confident in a long-term regulatory outlook and believe federal cannabis rescheduling represents one of the most significant catalysts for Curaleaf and the broader industry. The administrative law judge concluded the rescheduling hearings in July, and after a procedural delay, the final briefs in the ALJ process are due this week. We expect the administrative law judge to make his rescheduling recommendations shortly thereafter. While the process has taken longer than anticipated, historical precedents suggest the pace has moved quickly. Most importantly, our conviction in the merits of rescheduling and the magnitude of the opportunity remains unchanged. Beyond rescheduling itself, we anticipate greater clarity from Treasury regarding the tax treatment of adult-use cannabis. The financial implications for Curaleaf could be substantial with the potential to strengthen our balance sheet and expand our capacity to invest in growth. Last week, the DA began issuing registrations to medical cannabis operators in certain states. I am pleased to report that we have begun receiving registrations for our medical dispensaries. This marks an important milestone for Cureleaf and a meaningful step towards a healthier federally regulated cannabis marketplace. We thank Attorney General Todd Blanch for his continued commitment to advancing the rescheduling process. With our scale market leadership and improving operating fundamentals, we believe Cureleaf is exceptionally well positioned to capitalize on a more favorable federal regulatory environment. We made meaningful progress against our bill for growth priorities this quarter with solid growth across both our domestic and international business. I want to thank everyone across Curaleaf for their continued dedication and commitment. We remain focused on translating our progress into sustainable growth, robust margins, and long-term value for our shareholders. With that, I'll turn the call over to our President, Rahul Pinto, to discuss our domestic business in greater detail. Rahul?

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API